Osteopontin is a ligand for the alpha4beta1 integrin.
Recent work has shown that osteopontin expression is upregulated at sites of cardiovascular injury. It has been hypothesized that osteopontin provides an adhesive matrix for endothelial and smooth muscle cells during remodeling of the vascular wall following injury. Osteopontin has also been found to be synthesized by monocytes and macrophages within injury sites. Here, we present data showing that osteopontin can promote leukocyte adhesion through the alpha4beta1 integrin. In the presence of physiologic concentrations of Mg2+ and Ca2+, osteopontin purified from bovine milk promoted cell-substrate adhesion of HL-60 and Ramos cells, two model leukocyte cell lines. As with other adhesive ligands, adhesion to osteopontin required leukocyte activation. Under these conditions, no adhesion to control substrates such as bovine serum albumin was observed. Leukocyte adhesion was inhibited by anti-integrin antibodies directed at either the alpha4 or beta1 integrin subunits but not by control antibodies directed to other integrins. Further adhesion experiments revealed that leukocyte binding to osteopontin was completely inhibited by an alpha4beta1-binding peptide containing the leucine-aspartate-valine (LDV) sequence, while a control, non-binding peptide containing leucine-glutamate-valine (LEV) had minimal effects. Affinity chromatography using either surface labeled HL-60 or Ramos cell extracts revealed that the alpha4beta1 integrin specifically bound to osteopontin. Immunoprecipitation of eluted fractions from these columns positively identified the alpha4beta1 integrin. In order to localize potential alpha4beta1-binding sites within osteopontin, the protein was proteolytically cleaved with thrombin. A 30 kDa N-terminal osteopontin fragment purified using fast protein liquid chromatography promoted alpha4beta1 dependent leukocyte adhesion in a manner similar to that of the intact protein. These data collectively demonstrate that the alpha4beta1 integrin is a new adhesion receptor for osteopontin and that an alpha4beta1 binding site exists in the NH2-terminal thrombin fragment of osteopontin.
Bayless
K J
KJ
Microcirculation Research Institute, Texas A & M University Health Science Center, Texas A & M University, College Station, TX 77843-1114, USA.
Meininger
G A
GA
Scholtz
J M
JM
Davis
G E
GE
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001808:Blood Vessels / Q000293:injuries; D002417:Cattle; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D002846:Chromatography, Affinity; D018922:HL-60 Cells / Q000187:drug effects; D006335:Heart Injuries / Q000503:physiopathology; D006801:Humans; D039041:Integrin alpha4beta1; D016023:Integrins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D007962:Leukocytes / Q000187:drug effects* / Q000378:metabolism; D008024:Ligands; D053495:Osteopontin; D011485:Protein Binding; D016201:Receptors, Lymphocyte Homing / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D012710:Serum Albumin, Bovine / Q000378:metabolism; D012795:Sialoglycoproteins / Q000378:metabolism* / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology; D014945:Wound Healing / Q000502:physiology
D000911:Antibodies, Monoclonal; D039041:Integrin alpha4beta1; D016023:Integrins; D008024:Ligands; D016201:Receptors, Lymphocyte Homing; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D053495:Osteopontin; D012710:Serum Albumin, Bovine; D013917:Thrombin